Hatch-Waxman Safe Harbor Ruling Wrong In GSK Case, Solicitor General Says, But Should Not Be Reviewed
This article was originally published in The Pink Sheet Daily
Executive Summary
Supreme Court should not take up GlaxoSmithKline v. Classen given the Federal Circuit’s subsequent decision in Momenta v. Amphastar, the Solicitor General argues; Momenta plans to seek review of its case.
You may also be interested in...
Supreme Court Won’t Inoculate GSK In Hatch-Waxman Safe Harbor Case; Momenta May Have Better Shot
The high court also denied petitions seeking review of Otsuka’s Abilify patent and patents covering Cephalon’s Amrix; Supreme Court to hear oral arguments in generic preemption and “pay-for-delay” cases in March.
Supreme Court To Reconsider “Rules Of the Road” In Generic Preemption
Design defect claims made against generic companies are focus of a case involving Mutual Pharmaceutical’s generic sulindac; ruling may eliminate lower court carve-outs to its Mensing decision.
The End Of Pay-For-Delay? FTC Sees An Opportunity In AndroGel Lawsuit
Reverse payment settlements are a popular tactic for settling patent disputes between brand companies and their generic competitors. The Federal Trade Commission has aggressively (but mostly unsuccessfully) fought “pay-for-delay” deals in the courts, arguing that they drive up drug prices. Now FTC has its best chance yet at convincing the Supreme Court to hear the issue. Is this the end of pay-for-delay?